Triple Versus Dual Antiplatelet Therapy After Coronary Stenting Impact on Stent Thrombosis by Lee, Seung-Whan et al.
T
T
I
S
Y
C
J
S
C
o
I
(
s
t
a
a
o
s
t
s
r
e
c
e
t
M
R
P
a
Journal of the American College of Cardiology Vol. 46, No. 10, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Priple Versus Dual Antiplatelet
herapy After Coronary Stenting
mpact on Stent Thrombosis
eung-Whan Lee, MD, Seong-Wook Park, MD, PHD, FACC, Myeong-Ki Hong, MD, PHD,
oung-Hak Kim, MD, PHD, Bong-Ki Lee, MD, Jong-Min Song, MD, PHD, Ki Hoon Han, MD, PHD,
heol Whan Lee, MD, PHD, Duk-Hyun Kang, MD, PHD, Jae-Kwan Song, MD, PHD, FACC,
ae-Joong Kim, MD, PHD, Seung-Jung Park, MD, PHD, FACC
eoul, Korea
OBJECTIVES We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or
ticlopidine and cilostazol after coronary stenting.
BACKGROUND Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in
patients undergoing coronary stenting.
METHODS Patients undergoing successful coronary stenting were divided into dual antiplatelet therapy
(aspirin plus clopidogrel or ticlopidine, group I, n  1,597) and triple antiplatelet therapy
(aspirin plus clopidogrel or ticlopidine plus cilostazol, group II, n  1,415) groups. The
primary end point included death, myocardial infarction, target lesion revascularization, or
stent thrombosis within 30 days. The secondary end point was side effects of study drugs,
including major bleeding, vascular complication, hepatic dysfunction, and hematological
complications.
RESULTS Multi-vessel stenting and the use of long stents were more prevalent in group II than in group
I. The primary end point was 0.8% in group I and 0.3% in group II (p  0.085). Stent
thrombosis within 30 days was significantly lower in group II (n  1, 0.1%) than in group I
(n  9, 0.5%; p  0.024). The independent predictors of stent thrombosis were primary
stenting (odds ratio [OR] 7.9, 95% confidence interval [CI] 2.0 to 30.8, p 0.003) and triple
therapy (OR 0.12, 95% CI 0.015 to 0.98, p  0.048). The overall adverse drug effects,
including major bleeding, neutropenia, and thrombocytopenia, were no different between two
groups (1.8% vs. 2.6%, p  0.104).
CONCLUSIONS Compared with the dual antiplatelet regimen, triple antiplatelet therapy seemed to be more
effective in preventing thrombotic complications after stenting without an increased risk of
side effects. Triple antiplatelet therapy might be safely applied in patients or lesions with a
high risk of stent thrombosis. (J Am Coll Cardiol 2005;46:1833–7) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.048American College of Cardiology Foundation
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oilostazol is a potent oral antiplatelet agent with a rapid
nset of action that selectively inhibits phosphodiesterase
II, a mechanism different from adenosine diphosphate
ADP) receptor antagonists (1,2). Previous studies have
uggested that cilostazol has similar antiplatelet effects as
iclopidine (3) or clopidogrel (4). Adding cilostazol to
spirin and clopidogrel regimen was shown to provide
dditional suppression of the expression of P-selectin, a marker
f platelet activation, in 76.6% of study population, suggesting
ynergistic or additive antiplatelet effects (5). From these
heoretical, experimental, and clinical backgrounds, we as-
umed that triple antiplatelet therapy with aspirin, ADP-
eceptor antagonists, and cilostazol might have a beneficial
ffect on the prevention of thrombotic complications following
oronary stenting. Therefore, we evaluated the safety and
fficacy of triple antiplatelet therapy of aspirin, clopidogrel (or
iclopidine), and cilostazol compared with dual antiplatelet
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ccepted July 25, 2005.herapy with aspirin and clopidogrel (or ticlopidine) in patients
ndergoing successful coronary artery stenting.
ETHODS
tudy patients. From April 1998 to October 2003, 3,012
onsecutive patients who underwent successful coronary
tenting were eligible for this study. Inclusion criteria were
ymptomatic coronary artery disease or documented myo-
ardial ischemia, by treadmill exercise test or thallium
ingle-photon emission computerized tomography and an-
iographic evidence of 50% diameter stenosis or primary
tenting in patients with acute myocardial infarction (AMI)
nd postprocedure Thrombolysis In Myocardial Infarction
TIMI) flow grade 3. The criteria for exclusion were a
ontraindication to antiplatelet agents, severe left ventricular
ysfunction (ejection fraction 30%), left main coronary
rtery stenosis, known bleeding disorders, thrombocytope-
ia (150  109/l), severe hepatic or renal dysfunction
serum creatinine 2 mg/dl), administration of oral anti-
oagulants, glycoprotein IIb/IIIa receptor antagonists and
ther antiplatelet agents, and patients who underwent
rug-eluting stenting. All eligible patients who underwent
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Triple Antiplatelet Therapy After Stenting November 15, 2005:1833–7uccessful coronary stenting were divided into two groups: a
ual group (aspirin plus clopidogrel [n 868] or ticlopidine
n  729], group I, n  1,597), and a triple therapy group
aspirin plus cilostazol plus clopidogrel [n  502] or
iclopidine [n  913], group II, n  1,415). Aspirin and
lopidogrel (or ticlopidine) were started at least 2 days
efore stenting in patients who underwent elective stenting
n  2,536). In case of unplanned stenting, a loading dose
f each antiplatelet agent was administrated immediately
fter stenting (n  476). The loading/maintenance dose for
ach antiplatelet agent was 300 mg/75 mg q.d. for clopidogrel,
00 mg/250 mg b.i.d. for ticlopidine, and 200 mg/100 mg
.i.d. for cilostazol. Aspirin was given 200 mg once a day.
tent implantation procedure. Stents were deployed with
tandard techniques. During procedure, patients received
eparin to maintain the activated clotting time 250 s.
eparin was not continued after coronary stenting except
or the patients with ST-segment elevation AMI. In case of
rimary stenting, heparin was continuously infused for two
ays after the procedure.
uantitative coronary angiography analysis. Two experi-
nced angiographers who were unaware of the study goal
nalyzed the angiographic results with an on-line quantitative
ngiographic analysis system (ANCOR V2.0, Siemens, Ger-
any). Percent diameter stenosis, minimal lumen diameter,
nd reference diameter before and after stenting were measured
uring diastole after intracoronary nitroglycerin administration.
linical follow-up and events. All patients were seen as
utpatients 1 month after discharge. Complete blood count
nd blood biochemistry, including liver and renal function
ests, were performed before and 1 month after the proce-
ure. The primary end point was the incidence of primary
ardiac events, defined as stent thrombosis or major adverse
ardiac events (MACE), including death, myocardial in-
arction, and target lesion revascularization within one
onth. The secondary end points included peripheral vas-
ular complications, major bleeding, and any adverse events
neutropenia1.5 109/l, thrombocytopenia100 109/l,
kin rash, liver dysfunction, and gastrointestinal trouble). Acute
tent thrombosis was defined as thrombotic stent closure
ithin 24 h after stent deployment, and subacute stent throm-
osis was defined as thrombotic stent closure 24 h after the
rocedure. Myocardial infarction was diagnosed when creatine
inase-MB was elevated more than three-fold.
tatistical analysis. Analysis was performed on an intention-
o-treat basis. Data are expressed as mean  SD for continu-
us variables, and frequencies, for categorical variables. Con-
Abbreviations and Acronyms
ADP  adenosine diphosphate
AMI  acute myocardial infarction
CI  confidence interval
MACE  major adverse cardiac event
OR  odds ratioinuous variables were compared by the unpaired Student t test Mnd categorical variables by chi-square test or Fisher exact test.
ulti-variable logistic regression analysis was used to deter-
ine independent predictors for stent thrombosis. A two-
ided p value 0.05 was required for statistical significance.
ESULTS
aseline characteristics. There were no significant differ-
nces between the two groups in baseline clinical character-
stics except a higher prevalence of hypertension in group I
ersus group II (Table 1).
ngiographic and procedural characteristics. The pa-
ients in group II had more unfavorable anatomical and
rocedural characteristics than those in group I (Table 2). A
ong stent 30 mm was more frequently deployed in group
I, and the number of implanted stents per patient was also
igher in group II than in group I.
rimary end point at one month. A complete 30-day
ollow-up was available for all eligible patients. The primary
nd point of stent thrombosis or MACE was 0.8% in group
and 0.3% in group II (p  0.085). The incidence of stent
hrombosis was significantly lower in group II than in group
(0.5% in group I vs. 0.1% in group II, p  0.024) (Table
). Acute stent thrombosis occurred in three patients,
hereas subacute stent thrombosis occurred in seven pa-
ients, with a mean time of occurrence of 5.9  9.1 days
fter the procedure. Of all ten patients with stent throm-
osis, three (all from group I) had undergone primary
tenting for AMI, whereas the other seven (six in group I
nd one in group II) had undergone elective stenting (Table
). Eight patients died during the 30-day follow-up period:
ve (four cardiac deaths and one noncardiac death) in group
and three cardiac deaths in group II.
econdary end point at one month. Twenty-one patients
11 in group I and 10 in group II) experienced major
leeding requiring transfusion (Table 4). The secondary end
oint of the occurrence of adverse events was similar in both
roups (28 patients [1.8%] in group I vs. 37 patients [2.6%]
n group I; p  0.140). The incidence of adverse side effects
able 1. Baseline Clinical Characteristics
Variable, n
Dual
(n  1,597)
Triple
(n  1,415) p
ge, yrs 59  16 59  14 0.442
ender, male/female 1,147/450 1,016/399 0.990
isk factor
Diabetes mellitus 418 (26.2%) 331 (23.4%) 0.078
Hypertension 736 (46.1%) 599 (42.3%) 0.038
Hypercholesterolemia (total
cholesterol 200 mg/dl)
441 (27.6%) 379 (26.8%) 0.610
Current smoker 510 (31.9%) 459 (32.4%) 0.768
linical presentation 0.198
Stable angina pectoris 554 (34.7%) 512 (36.2%)
Unstable angina pectoris 720 (45.1%) 653 (46.1%)
Acute myocardial infarction 323 (20.2%) 250 (17.7%)
rimary stenting 85 (5.3%) 72 (5.1%) 0.773
eft ventricular ejection fraction 58  10% 59  10% 0.135
ulti-vessel stenting 469 (29.4%) 477 (33.7%) 0.01
r
g
g
w
P
g
t
d
s
i
t
D
T
s
a
e
g
a
T
d
a
t
0
b
l
s
m
t
t
T
M
L
N
T
S
G
L
an He
T
S
M
P
1835JACC Vol. 46, No. 10, 2005 Lee et al.
November 15, 2005:1833–7 Triple Antiplatelet Therapy After Stentingequiring termination of medication was similar in both
roups, 11 patients (0.7%) in group I vs. 7 patients (0.5%) in
roup II (p  0.490). These side effects resolved after drug
ithdrawal and supportive care.
redictors of stent thrombosis. All clinical and angio-
raphic variables with p  0.2 in univariate analysis were
ested. On the multi-variable analysis, the independent pre-
ictors of stent thrombosis were primary stenting in the
etting of AMI (odds ratio [OR] 7.9, 95% confidence
nterval [CI] 2.0 to 30.8, p  0.003) and triple antiplatelet
herapy (OR 0.12, 95% CI 0.015 to 0.98, p  0.048).
ISCUSSION
his study demonstrates that triple antiplatelet therapy
eems to be more effective in preventing stent thrombosis
Table 2. Baseline Angiographic and Procedura
Variable, n (n 
Number of stents used
Treated artery
Left anterior descending 1
Left circumflex
Right coronary
AHA/ACC lesion type
A
B1
B2
C
Lesion length, mm 1
Small vessels (3.0 mm)
Chronic total occlusion
Long stent (30 mm)
Reference artery size, mm
Minimal lumen diameter, mm
Baseline
Final
Balloon artery ratio
Maximum inflation pressure, atmosphere
Number of stent/patient
1 1
2
3 or more
Stent/patient (mean)
ACC  American College of Cardiology; AHA  Americ
able 3. Primary End Points During Follow-Up
Dual
(n  1,597)
Triple
(n  1,415) p
tent thrombosis 9 (0.5%) 1 (0.1%) 0.024
Acute stent occlusion 3 (0.2%) 0 0.252
Subacute stent thrombosis 6 (0.3%) 1 (0.1%) 0.223
ajor cardiac events
Myocardial infarction 11 (0.7%) 3 (0.2%) 0.063
Target lesion revascularization 9 (0.5%) 1 (0.1%) 0.024
Repeat intervention 8 (0.6%) 1 (0.1%)
Emergency bypass 1 (0.02) 0
Death 5 (0.3%) 3 (0.2%) 0.730
Orimary end point 13 (0.8%) 4 (0.3%) 0.085fter coronary stenting, without an increased risk of side
ffects compared with the dual antiplatelet regimen.
The incidence of MACE was lower in the triple therapy
roup (0.8% in group I and 0.3% in group II, p  0.085),
lthough it did not reach to a statistically significant level.
riple antiplatelet therapy significantly reduced the inci-
ence of stent thrombosis when compared with dual ther-
py. Triple therapy was an independent predictor of stent
hrombosis by multi-variable analysis (OR 0.12, 95% CI
.015 to 0.98, p  0.048). The incidence of stent throm-
osis (1 of 1,415, 0.1%) in the triple group is also much
ower than the anecdotal reports of 0.4% to 2.0% in previous
tudies with dual antiplatelet therapy (6,7). These results
ight provide the rationale for using triple antiplatelet
herapy in patients or lesions with a high-risk of stent
hrombosis.
able 4. Secondary End Points During Follow-Up
Dual
(n  1,597)
Triple
(n  1,415) p
ajor bleeding 10 (0.6%) 11 (0.8%) 0.621
ocal vascular complication 0.693
Aneurysm 6 (0.3%) 1 (0.1%)
Arteriovenous fistula 3 (0.2%) 3 (0.2%)
eutropenia (1.5  109/l) 3 (0.2%) 2 (0.1%) 1
hrombocytopenia (100  109/l) 4 (0.2%) 2 (0.1%) 0.691
kin rash 8 (0.5%) 15 (1.1%) 0.079
astrointestinal disorder 8 (0.5%) 3 (0.2%) 0.560
iver enzyme elevation 2 (0.1%) 1 (0.1%) 1
aracteristics
ual
5 lesions)
Triple
(n  2,030 lesions) p
237 2,207
0.001
(66.9%) 1,486 (73.2%)
(12.6%) 181 (8.9%)
(20.5%) 363 (17.9%)
0.040
(17.7%) 327 (16.1%)
(25.3%) 459 (22.6%)
(20.1%) 414 (20.4%)
(36.9%) 830 (40.9%)
 6.49 19.86  7.79 0.116
(25.8%) 544 (26.8%) 0.501
(10.4%) 195 (9.6%) 0.384
(14.9%) 404 (18.3%) 0.004
 0.60 3.24  0.92 0.154
 0.53 0.91  0.55 0.001
 0.57 3.17  0.84 0.073
 0.22 1.11  0.23 0.326
 3 12  3 0.926
0.005
(66.1%) 816 (57.7%)
(29.5%) 436 (30.8%)
(4.4%) 163 (11.5%)
.40 1.56 0.000
art Association.l Ch
D
2,19
2,
,468
277
450
389
555
441
810
9.49
566
228
333
3.19
0.83
3.12
1.14
12
,056
471
70
1verall events 28 (1.8%) 37 (2.6%) 0.104
h
A
s
o
a
s
i
a
s
c
p

t
p
n
a
a
n
h
a
r
e
c
p
g
a
a
a
a
a
s
r
a
p
p
r
r
r
c
d
p
o
a
a
m
g
p
c
o
o
s
m
l
r
s
t
r
n
a
t
g
o
i
t
r
t
n
w
a
l
R
D
c
S
R
1
1
1836 Lee et al. JACC Vol. 46, No. 10, 2005
Triple Antiplatelet Therapy After Stenting November 15, 2005:1833–7The incidence of stent thrombosis was significantly
igher in patients who underwent primary stenting for
MI (3 of 157, 1.9%) than in patients without primary
tenting (7 of 2,855, 0.2%; p  0.013). A high incidence
f stent thrombosis in primary stenting was also shown in
previous randomized trial (4). Moreover, in the current
tudy, primary stenting for AMI was found to be one of the
ndependent predictors for stent thrombosis. The high prob-
bility of stent thrombosis in AMI has been suggested in
tudies showing that even a large loading dose (600 mg) of
lopidogrel did not inhibit aggregation and degranulation of
latelets by thrombin-related activating peptides (25
mol/l) in an environment of high thrombin activity (8) and
hat marked increased platelet reactivity was observed in
atients with AMI undergoing primary percutaneous coro-
ary intervention (9). Considering these results, it would be
reasonable approach to add other potent antiplatelet
gents to aspirin and ADP receptor antagonists after coro-
ary stenting in patients with a high thrombin burden or
igh risk of stent thrombosis.
The exact mechanism of beneficial effects of triple
ntiplatelet therapy remains uncertain. Previous studies
eported that elevated cyclic adenosine monophosphate,
ither by inhibiting ADP-induced inhibition of adenylate
yclase by ADP-receptor antagonist or inhibiting phos-
hodiesterase III by cilostazol, inhibited platelet aggre-
ation and P-selectin release induced by thrombin, ADP,
nd thromboxane A2 (10,11). A marker of platelet
ctivation, P-selectin is expressed exclusively by platelet
ctivation, promotes fibrin deposition, and leads to the
ccumulation of leucocytes in areas of vascular injury and
rterial thrombogenesis (12). A recent report demon-
trated that adding cilostazol to aspirin and clopidogrel
egimen reduced platelet activation below the level
chieved by aspirin and clopidogrel via additional sup-
ression of P-selectin expression (5). The incidence of
oor suppression of P-selectin expression by clopidogrel
anged from 29% to 100% (13,14). These previous
eports support the enhanced antiplatelet effects of triple
egimen. Furthermore, like ADP-receptor antagonist,
ilostazol significantly inhibited platelet aggregation in-
uced by ADP and other agonists, which suggests the
ossibility of a synergistic or additive effect for inhibition
f platelet aggregation in response to ADP and other
gonists (15).
The clinical benefit of triple therapy might be offset by
n associated increase in major bleeding. The rate of
ajor bleeding, however, was similar between the two
roups. This result might be partially explained by a
revious study showing that, compared with clopidogrel,
ilostazol had similarly effective antiplatelet action with-
ut a significant increase in bleeding time (15). The
verall incidence of adverse drug reactions was also
imilar between the two groups. Therefore, cilostazolight be safely added to the conventional dual antiplate-
et regimen after coronary stenting in patients with high
isk for stent thrombosis.
A few limitations need to be addressed. First, definitive
tatements may not be made regarding efficacy or applica-
ion of the results, directly to patients or lesions with a high
isk of stent thrombosis, because of the non-randomized
ature of the retrospective evaluation. Second, despite the
pparently large sample size, this study was underpowered
o prove meaningful differences in MACE between two
roups. Third, the study drugs were administered with an
pen-label, making bias possible. Prospective random-
zed trials should be done to confirm the effects of the
riple antiplatelet regimen in patients or lesions with high
isk of stent thrombosis. Finally, the beneficial effects of
he triple antiplatelet regimen in bare metal stenting may
ot be extrapolated to drug-eluting stenting. It would be
orth evaluating the efficacy of triple antiplatelet therapy
fter drug-eluting stenting, particularly in patients or
esions with a high risk of stent thrombosis.
eprint requests and correspondence: Dr. Seong-Wook Park,
epartment of Medicine, University of Ulsan, College of Medi-
ine, Asan Medical Center, 388-1 Poongnap-dong, Songpa-gu,
eoul, 138-736, Korea. E-mail: swpark@amc.seoul.kr.
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